Once the decision is made to deploy amikacin in a patient with refractory MAC lung disease, what do we know about the problematic/toxicity/adherence and side effect pitfalls of IV amikacin, based on results of the CONVERT trial?

Once the decision is made to deploy amikacin in a patient with refractory MAC lung disease, what do we know about the problematic/toxicity/adherence and side effect pitfalls of IV amikacin, based on results of the CONVERT trial?

Once the decision is made to deploy amikacin in a patient with refractory MAC lung disease, what do we know about the problematic/toxicity/adherence and side effect pitfalls of IV amikacin, based on results of the CONVERT trial?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Julie Philley, MD

Julie Philley, MD

Chair of the Department of Medicine
Chief of Pulmonary and Critical Care
UT Health North Campus Tyler
The University of Texas Health Sciences Center
Houston, Texas